CME article by Andrew W. Goddard, M.D., Professor of Psychiatry and Radiology, Department of Psychiatry, Indiana University School of Medicine, and Director, Adult Psychiatry Clinic, University Hospital; Anantha Shekhar, M.D., Ph.D., Professor of Psychiatry, Pharmacology, and Neurobiology, Department of Psychiatry, Indiana University School of Medicine; Amit Anand, M.D., Associate Professor of Psychiatry and Radiology, Department of Psychiatry, Indiana University School of Medicine; Kelda Walsh, M.D., Clinical Professor of Psychiatry, Department of Psychiatry, Indiana University School of Medicine; and Christopher J. McDougle, M.D., Albert E. Stern Professor and Chairman, Department of Psychiatry, Indiana University School of Medicine
Dr. Goddard has disclosed that he receives grant/research support from, is a consultant to, and is on the speakers' bureau for Pfizer. Dr. Anand has disclosed that he receives grant/research support from GlaxoSmithKline and Elan Pharmaceuticals and receives an honorarium from Pfizer. Dr. McDougle has disclosed that he receives grant/research support from Pfizer, Janssen, and Eli Lilly; is a consultant to Janssen and Eli Lilly; and is on the speakers' bureau for Pfizer and Janssen. Drs. Shekhar and Walsh have disclosed that they have no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity.
The authors have further disclosed that the use of gabapentin for panic and social anxiety, risperidone for obsessive-compulsive disorder, and propranolol for post-traumatic stress disorder has not been approved by the U.S. Food and Drug Administration.
